FDA Enforcement Class I Completed

Leccurate SARS-CoV-2, Antigen Rapid Test Kit (Colloidal Gold Immunochromatography), 1 test, IVD. for the qualitative detection of antigen SARS-CoV-2 in clinical samples (nasal swab).

Recall: Z-1620-2021 · Reported June 9, 2021

Enforcement

Recall Number
Z-1620-2021
Event ID
87737
Classification
Class I
Status
Completed
Product Type
Devices
Firm
LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD
Voluntary / Mandated
Voluntary: Firm initiated
Initial Notification
E-Mail
Report Date
June 9, 2021
Initiation Date
April 26, 2021
Classification Date
May 28, 2021
Address
Building 7-1, NO. 37 Chaoqian Rd; Changping Tech Zone, Beijing, N/A, China

Description

Leccurate SARS-CoV-2, Antigen Rapid Test Kit (Colloidal Gold Immunochromatography), 1 test, IVD. for the qualitative detection of antigen SARS-CoV-2 in clinical samples (nasal swab).

Reason

Antigen Rapid Test Kit is not authorized, cleared, or approved for marketing and/or distribution in the U.S.

Code Info

All Lots distributed within the U.S.

Distribution

Worldwide Distribution: US Distribution to states of: FL, IL, NY, GA, Puerto Rico and OUS countries of: Canada, Honduras, Peru, Dominican, Bolivia, Colombia, Mexico, Brazil, Argentina, Guatemala, Venezuela, Ecuador, Chile, Paraguay, Panama, Costa Rica, Peru and Hong Kong.

Quantity

8, 419, 545 units in total